Status
Conditions
Treatments
About
To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES).
Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
1,500 participants in 2 patient groups
Loading...
Central trial contact
Ken Kozuma, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal